Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Urogen Pharma (URGN) had Revenue of $37.84M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$37.84M
Net Income	$-26.36M
Cost of Goods Sold	$3.29M
Gross Profit	$34.55M
Operating Expenses	$56.95M
Operating Income	$-19.11M
Non-Operating Income/Expense	$-7.52M
Pre-Tax Income	$-26.64M
Normalized Pre-Tax Income	$-26.64M
Income after Taxes	$-26.36M
Income from Continuous Operations	$-26.36M
Consolidated Net Income/Loss	$-26.36M
Normalized Income after Taxes	$-26.36M
EBIT	$-19.11M
EBITDA	$-19.11M
Weighted-Average Shares Outstanding (Basic)	48.12M
Weighted-Average Shares Outstanding (Diluted)	48.12M
Earnings per Share (EPS) (Basic)	$-0.53
Earnings per Share (EPS) (Diluted)	$-0.53
Balance Sheet Financials
Current Assets	$186.02M
Property, Plant, and Equipment	$0.64M
Long-Term Assets	$14.43M
Total Assets	$200.46M
Current Liabilities	$46.42M
Long-Term Debt	$122.21M
Long-Term Liabilities	$259.51M
Total Liabilities	$305.93M
Common Equity	$-105.47M
Tangible Shareholders Equity	$-105.47M
Shareholders Equity	$-105.47M
Common Shares Outstanding	48.35M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-162.44M
Cash Flow from Investing Activities	$61.56M
Cash Flow from Financial Activities	$39.92M
Beginning Cash	$173.06M
End Cash	$112.09M
Increase/Decrease in Cash	$-60.97M
Stock-Based Compensation	$11.96M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	4.01
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	7.30
Debt to Equity Ratio	-1.16
Gross Margin	91.31%
Operating Margin	-50.52%
EBIT Margin	-50.52%
EBITDA Margin	--
Pre-Tax Profit Margin	-70.40%
Profit Margin	-69.68%
Free Cash Flow	$-162.73M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.19
Inventory Turnover	0.20
Receiveable Turnover	1.14
Days Sales in Receivables	78.69
Return on Equity	25.00%
Return on Tangible Equity	25.00%
Return on Assets	-13.15%
Return on Investments	-157.53%
Book Value Per Share	$-2.18
Free Cash Flow per Share	$-3.38
Operating Cash Flow per Share	$-3.38

Data from Zacks Investment Research, Inc.